NCT06959433Not yet recruitingPhase 3
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Safety and Efficacy of Lu-177 PSMA Treatment in Metastatic Clear Cell Renal Carcinoma
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
Summary Renal Cell Carcinoma (RCC) consists of 2% of all malignencies. RCCs are generally divided to histopathological subtypes as clear cell and non-clear cell variants. Clear cell variant responsible for the 75-80% of all RCCs. It is reported that 20-30% of RCCs are metastatic at the diagnosis and 5 years survival is approximately is 10-20% in this group of patients. Moreover, 60% of patients who are not metastatic at the diagnosis, develop metastates within 2-3 years. 2nd and 3th line effective treatment option in metastatic RCCs patients has been a subject of interest. PSMA (protatate specific membrane antigen) with the other name glutamate carboxypeptidase, is a transmembrane protein and overexpresses in prostate adenocarcinomas and neoangiogenesis spots of endothelium of other several tumor types. It infronts as a target for theranostic consept for mainly prostate cancer in nuclear medicine. As a radionuclide treatment option, Lu-177 PSMA treatment is proved as safe and effective treatment option in castration resistant prostata cancer patients. After its widely use in prostate cancer, it is reported that PSMA molecule can be used for imaging of RCC patients and PSMA uptake is higher than 18F-FDG. For this reason, Lu-177 PSMA treatment can be a systemic treatment option in RCC patients who have progress afer 1st cycle treatment. In this study we aimed to safety and efficacy of Lu-177 PSMA treatment in metastatic RCC patients as systemic radionuclide treatment option.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 28 Apr 2025
- Start date
- 1 May 2026
- Primary completion date
- 1 Feb 2028
- Lead sponsor
- Ankara University
- Diseases
- Kidney cancer
- NCT number
- NCT06959433
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 20
- From 1 May 2026 to the primary completion date, 1 Feb 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Not having received any systemic therapies
- Any contraindication for radionuclide therapy (pregnancy, lactation, organ disfunction, metastatic lesions with a risk of compression
- Previous history of any radionuclide therapies
Other illness
- History of a secondary malignancy
Age
- Age\<18
Other
- ECOG performance status \> 2
- Inability to sign informed consent
Who the study is looking for
- Age \>18
- Progression after at least 2 lines of systemic therapy or existence of a contraindication to systemic therapies
- At least 3 years of life expectancy
- ECOG performance status ≤ 2
- Ability to sign informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.